← Back to Clinical Trials
Recruiting Phase 1, Phase 2 NCT07451613

NCT07451613 Safety and Tolerability Study of Human Neural Stem Cells for Huntington's Disease

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07451613
Status Recruiting
Phase Phase 1, Phase 2
Sponsor Leslie Thompson
Condition Huntington Disease
Study Type INTERVENTIONAL
Enrollment 21 participants
Start Date 2026-04-06
Primary Completion 2028-06

Trial Parameters

Condition Huntington Disease
Sponsor Leslie Thompson
Study Type INTERVENTIONAL
Phase Phase 1, Phase 2
Enrollment 21
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2026-04-06
Completion 2028-06
Interventions
hNSC-01

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this research study is to determine whether an implantation of hNSC-01 is a safe and tolerable study intervention for Huntington's disease. This study is the first time that hNSC-01 is being tested in people.

Eligibility Criteria

Please note this may not be a complete list of eligibility criteria. Inclusion Criteria: * Have decision-making capacity and be able to provide written informed consent. * Are between 18 to 65 years of age * Have genetically confirmed diagnosis of Huntington's Disease * Able to undergo MRI scans, tolerate neurosurgical procedure, blood draws and lumbar puncture. Exclusion Criteria: * Are pregnant * Test positive for human immunodeficiency virus (HIV), hepatitis C or chronic hepatitis B at Screening * Have an implanted deep brain stimulation device.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology